

### Key investor information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.



## Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF

**Share class: 1C, ISIN: IE000KD0BZ68, Security code: DBX0R2, Currency: USD**

a sub-fund of Xtrackers (IE) plc. The management company is DWS Investment S.A., a member of the DWS Group.

### Objectives and investment policy

The fund is passively managed. The aim is for your investment to track the performance before fees and expenses of the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index (index). The index is based on the MSCI ACWI IMI Index (Parent Index) and is designed to reflect the performance of the shares of large, medium, and small-capitalisation companies globally that derive, or are expected to derive, significant revenues from technological innovation in the genomic healthcare sector. In order to be eligible for inclusion in the index, companies must be eligible for inclusion in the Parent Index and pass both thematic selection criteria and ESG screening criteria. The thematic selection criteria calculates a relevance score for potential constituents by assessing companies' exposure to business activities associated with the theme. Securities must meet a certain relevance score threshold to be eligible for inclusion. The ESG screening criteria excludes companies from the Parent Index, which: (i) are unrated by MSCI ESG Research; (ii) are assigned an MSCI ESG Rating of CCC; (iii) have any involvement in controversial weapons; (iv) are classified by MSCI in their Business Involvement Screening Research as breaching certain revenue thresholds in controversial activities, including, but not limited to, tobacco, conventional weapons, nuclear weapons, civilian firearms, thermal coal and oil sands extraction; and/or (v) fail to comply with the United Nations Global

Compact principles. The remaining securities are then ranked by their market capitalisation and the top 100 are selected for inclusion. Securities are finally weighted by a product of their free-float adjusted market capitalisation and their relevance score. The index includes an issuer capping component, limiting the weight of each issuer to 4.5% at each quarterly rebalance. The index is administered by MSCI Limited. The index is calculated on a total return net basis, which means that all dividends and distributions by the companies are reinvested in the shares after tax. The index is reviewed semi-annually and rebalanced at least quarterly. The index is calculated in USD on a daily basis. To achieve the aim, the fund will attempt to replicate the index, before fees and expenses, by buying all or a substantial number of the securities in the index. The fund may employ techniques and instruments in order to manage risk, reduce costs and improve results. These techniques and instruments may include the use of financial contracts (derivatives). The fund may also engage in secured lending of its investments to certain eligible third parties subject to certain ESG criteria to generate additional income to offset the costs of the fund. The currency of the fund is USD. Returns and gains are not distributed but are reinvested in the fund. You may request the redemption of shares generally on a daily basis.

### Risk and reward profile



The calculation of the risk and reward profile is based on simulated data that cannot be used as a reliable indicator for the future risk

profile. This risk indicator is subject to changes; the classification of the fund may change over time and cannot be guaranteed. Even a fund that is classified in the lowest category (category 1) does not represent a completely risk-free investment. The fund is classified in category 6 because its share price may fluctuate strongly and the likelihood of both losses and gains may therefore be high.

### Charges

The charges you pay are used to pay the costs of running the fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest	
<b>Entry charge</b>	None
<b>Exit charge</b>	None
This is the maximum that might be taken out of your money before it is invested (entry charge) and before the proceeds of your investment are paid out (exit charge).	
Charges taken from the fund over a year	
<b>Ongoing charges</b>	0.35 %
Charges taken from the fund under certain specific conditions	
<b>Performance fee</b>	None
<b>Securities lending fees</b>	0.00 %

Secondary market investors (those who buy or sell shares on a stock exchange) may be charged certain fees by their stock broker. These charges, if any, can be obtained from such stock broker. Authorised participants dealing directly with the fund will pay the transaction costs related to their subscriptions and redemptions.

The ongoing charges shown here are a cost estimate. It excludes portfolio transaction costs and performance fees, if any.

Additional information on costs can be found in the cost section(s) of the prospectus.

To the extent the fund undertakes securities lending to generate revenue, the fund will ultimately be allocated 70% of the associated revenue, the securities lending agent, which will be a DWS entity or other Deutsche Bank entity, will be allocated 15% and the remaining 15% will be allocated to the DWS entity which monitors such activities, as set out in the prospectus. As securities lending revenue sharing does not increase the costs of running the fund, this has been excluded from the ongoing charges.

### Past performance

There is not yet sufficient data available to provide you with useful information regarding earlier performance.

The 1C share class of Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF was launched in 2022.

### Practical information

The depositary is State Street Custodial Services (Ireland) Limited, Ireland. Copies of the prospectus and the periodic reports are available free of charge in the language of this document. The documents as well as other information (including the latest share prices as well as the indicative net asset values) are available free of charge. The documents are available on your local DWS website or at [www.Xtrackers.com](http://www.Xtrackers.com). Information on the current remuneration policy of the management company, including a description of how

remuneration and benefits are calculated is published on the Internet at <https://www.dws.com/footer/Legal-Resources/dws-remuneration-policy?setLanguage=en>. The information will be sent to you in paper form free of charge upon request. The taxation regime applicable to the fund in Ireland may affect your personal tax situation. Xtrackers (IE) plc may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the

sales prospectus. This fund is a sub-fund of Xtrackers (IE) plc for which the prospectus and the periodic reports are prepared as a whole. The assets and liabilities of each sub-fund are segregated by law. As a result, assets of one sub-fund are not available in the event of claims against or insolvency of another. More share classes may be available for this fund - please refer to the relevant

section of the prospectus for further details. You are not permitted to exchange your shares in this fund for other funds of Xtrackers (IE) plc. This fund is authorised in Ireland and is regulated by the Central Bank of Ireland. DWS Investment S.A. is authorised in Luxembourg and is regulated by the Commission de Surveillance du Secteur Financier.

This key investor information is accurate as at 13.07.2022.

The MSCI indices are the exclusive property of MSCI Inc. and its subsidiaries (MSCI) and may not be reproduced or extracted and used for any other purpose without MSCI's consent. The fund is not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to the fund or any index on which such fund is based. The MSCI indices are provided without any warranties of any kind.